Oocyte Vitrification for Fertility Preservation in Women with Benign Gynecologic Disease: National Clinical Practice Guidelines Developed by a Modified Delphi Consensus Process

Blandine Courbière, Énora Le Roux, Emmanuelle Mathieu d’Argent, Antoine Torre, Catherine Patrat, C. Poncelet, Jacques Montagut, Anne‐Sophie Grémeau, H. Creux, Maëliss Peigné, Isabella Chanavaz‐Lacheray, Lara Dirian, Xavier Fritel, Jean‐Luc Pouly, Arnaud Fauconnier
2021 · doi:10.20944/preprints202107.0125.v1 · W3196501830
preprint OA: green CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study utilized a modified Delphi process to develop guidelines for oocyte vitrification for fertility preservation in women with benign gynecologic diseases, informing them about risks and birth likelihood by age.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

International guidelines are published in oncology to provide standardized information and fertility preservation (FP) care for adults and children with cancer. For benign gynecologic diseases (BGD), many recommendations are based on data coming from oncofertility studies rather than studies with a stronger and broader evidence base. The purpose of the study was to conduct a modified Delphi process for generating FP guidelines for BGD. A steering committee identified 42 potential FP practices for BGD. Then 114 key stakeholders were asked to participate in a modified Delphi process via two online survey rounds and a final meeting. Consensus was reached for 28 items. Among them, stakeholders rated age-specific information concerning the risk of diminished ovarian reserve after surgery as important but rejected proposals setting various upper and lower age limits for FP. All women should be informed about the benefit/risk balance of oocyte vitrification, in particular about the likelihood of live birth according to age. FP should not be offered in rASRM stages I and II endometriosis without endometriomas. These guidelines could be useful for gynecologists to identify situations at risk of infertility and to better inform women with BGDs who might need personalized counseling for FP.

My notes (saved in your browser only)

Outcome instruments

rASRM

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-14T06:08:20.186862+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK